Biologic therapies in type 1 diabetes: how far are they from us?
Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, Hunan 410011, China.
Chao
C
Deng
Yu-Fei
YF
Xiang
Zhi-Guang
ZG
Zhou
D000069594:Abatacept; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D001691:Biological Therapy / Q000379:methods*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D000069283:Rituximab
D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018796:Immunoconjugates; D000069283:Rituximab; D000069594:Abatacept; C550701:otelixizumab; C502540:teplizumab